Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Hansson

Showing results (111-120 of 199) with videos related to

Pageof 20
Sort By:
Cancer Research|February 12, 2004
Induction of melanoma phenotypes in human skin by growth factors and ultraviolet BCarola Berking, Richelle Takemoto, Kapaettu Satyamoorthy, et al.
Cancer Immunology, Immunotherapy : CII|April 3, 2015
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trialLina Prasmickaite, Gisle Berge, Ingrid J Bettum, et al.
Journal of Dermatological Science|September 3, 2013
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanomaAbdlsattar Zebary, Katarina Omholt, Ismini Vassilaki, et al.
Pigment Cell & Melanoma Research|December 17, 2008
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parametersVeronica Höiom, Rainer Tuominen, Max Käller, et al.
Genes, Chromosomes & Cancer|January 24, 2013
Hereditary uveal melanoma: a report of a germline mutation in BAP1Veronica Höiom, Daniel Edsgärd, Hildur Helgadottir, et al.
Cancer Epidemiology|January 23, 2014
Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based studyTherese M-L Andersson, Hanna Eriksson, Johan Hansson, et al.
Cell Death & Disease|October 21, 2020
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanomaIshani Das, Huiqin Chen, Gianluca Maddalo, et al.
Journal of Health Organization and Management|August 4, 2012
Implementing organisation and management innovations in Swedish healthcare: lessons from a comparison of 12 casesJohn Øvretveit, Magna Andreen-Sachs, Jan Carlsson, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2014
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levelsPia Vihinen, Taina Tervahartiala, Timo Sorsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from SwedenHanna Eriksson, Johan Lyth, Eva Månsson-Brahme, et al.
Pageof 20

Showing results (111-120 of 199) with videos related to

Sort By:
Pageof 20
Cancer Research|February 12, 2004
Induction of melanoma phenotypes in human skin by growth factors and ultraviolet BCarola Berking, Richelle Takemoto, Kapaettu Satyamoorthy, et al.
Cancer Immunology, Immunotherapy : CII|April 3, 2015
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trialLina Prasmickaite, Gisle Berge, Ingrid J Bettum, et al.
Journal of Dermatological Science|September 3, 2013
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanomaAbdlsattar Zebary, Katarina Omholt, Ismini Vassilaki, et al.
Pigment Cell & Melanoma Research|December 17, 2008
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parametersVeronica Höiom, Rainer Tuominen, Max Käller, et al.
Genes, Chromosomes & Cancer|January 24, 2013
Hereditary uveal melanoma: a report of a germline mutation in BAP1Veronica Höiom, Daniel Edsgärd, Hildur Helgadottir, et al.
Cancer Epidemiology|January 23, 2014
Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based studyTherese M-L Andersson, Hanna Eriksson, Johan Hansson, et al.
Cell Death & Disease|October 21, 2020
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanomaIshani Das, Huiqin Chen, Gianluca Maddalo, et al.
Journal of Health Organization and Management|August 4, 2012
Implementing organisation and management innovations in Swedish healthcare: lessons from a comparison of 12 casesJohn Øvretveit, Magna Andreen-Sachs, Jan Carlsson, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2014
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levelsPia Vihinen, Taina Tervahartiala, Timo Sorsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from SwedenHanna Eriksson, Johan Lyth, Eva Månsson-Brahme, et al.
Pageof 20